Business Today
Subscribe
PMS TodayUS NewsIndiaUPSTARTWeatherBT ShortsNRIEducationElection
BT GolfBT MindrushBT Best Banks
Search

COMPANIES

No Data Found

NEWS

No Data Found
Advertisement
News
markets
stocks
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd

Aurobindo Pharma Ltd (AUROPHARMA) Share Price

  • Sector: Pharmaceuticals (Mid Cap)
  • Volume: 7,80,001
Apr 25, 2025
  • NSE
  • BSE
Share
  • Whatsapp
  • Twitter
  • Facebook
₹1,220.10
₹-37.70 (-3.00%)
1,210.00Low
Today’s Performance
1,268.90High
1,010.00Low
52 Week’s Performance
1,592.00High

bt_logoStock Analysis

bt_logoStock Performance

  • 1 Day-3.00%
  • 1 Week1.57%
  • 1 Month2.10%
  • 3 Months3.72%
  • 6 Months-14.57%
  • 1 Year10.58%
  • 3 Years24.07%
  • 5 Years14.00%

bt_logoCompany Stories

Aurobindo Pharma arm Eugia gets USFDA nod for Dasatinib tablets, eyes $1.8 billion marketEugia Pharma, a subsidiary of Aurobindo Pharma, has secured final USFDA approval for manufacturing and marketing Dasatinib Tablets.Aurobindo Pharma shares were up 2.65 per cent at Rs 1,219.60.
View more

bt_logoPeer Comparison

Price

bt_logoStock Summary

  • Face Value (₹)1.00
  • Beta0.84
  • 52-Week Low (₹)1,010.00
  • 52-Week High (₹)1,592.00
  • Price-to-Book (X)*2.31
  • Dividend Yield (%)0.37
  • Price-to-Earnings (P/E) (X)*20.44
  • Earnings Per Share (₹)59.58
  • Market Cap (₹ Cr.)*71,490.37
* Values as of last close price

bt_logoCOMPETITORS

BT TV

Trump Tariff| Kenneth Andrade on India’s Resilience Amid Trade Uncertaint1:33Trump Tariff | Kenneth Andrade on India’s Resilience Amid Trade Uncertainty
Being Polite To ChatGPT Could Be Costing Millions: The Shocking Reality Behind AI's Hidden Energy4:38Being Polite To ChatGPT Could Be Costing Millions: The Shocking Reality Behind AI's Hidden Energy
Understanding The Impact Of India’s Suspension Of The Indus Water Treaty On Pakistan5:16Understanding The Impact Of India’s Suspension Of The Indus Water Treaty On Pakistan
Jim Rogers: India’s Shift Toward Prosperity Makes Its Market a Global Investor’s Dream0:54Jim Rogers: India’s Shift Toward Prosperity Makes Its Market a Global Investor’s Dream
From Cement To Coal: Best Domestic Plays Amid Global Trade Uncertainty1:43From Cement To Coal: Best Domestic Plays Amid Global Trade Uncertainty
Pahalgam Attack: Emotional Burst Of Victims, Survivors & Kashmiri Locals2:58Pahalgam Attack: Emotional Burst Of Victims, Survivors & Kashmiri Locals
Domestic Focus, Global Reach: Jindal Stainless8:54Domestic Focus, Global Reach: Jindal Stainless
Piyush Goyal Urges Industry To Back 'Make In India', Warns Against Irregular Trade Practices3:40Piyush Goyal Urges Industry To Back 'Make In India', Warns Against Irregular Trade Practices
Nine Indian Banks Among Forty Global Digital Champions: Deloitte Report19:05Nine Indian Banks Among Forty Global Digital Champions: Deloitte Report
India-Pak Tensions Rattle Markets | Sensex Tanks 400 Pts, Nifty Sees Sharp Drop8:47India-Pak Tensions Rattle Markets | Sensex Tanks 400 Pts, Nifty Sees Sharp Drop
View more

bt_logoFinancial Analysis

Income Statement (₹ Cr.)

No data for consolidated quarterly .

Balance Sheet (₹ Cr.)

No data for consolidated quarterly .

Cash Flow (₹ Cr.)

No data for consolidated quarterly .

bt_logoRatio Analysis

Return on Equity (%)
No Data For consolidated ROE.
Return on Assets (%)
No Data For consolidated ROE.
Price-to-Earnings (P/E) (X)
No Data For consolidated ROE.
Price to Book (x)
No Data For consolidated ROE.
Return on Capital Employed (%)
No Data For consolidated ROE.
Enterprise Value to EBITDA (X)
No Data For consolidated ROE.
Net Profit Margin (%)
No Data For consolidated ROE.
Gross Profit Margin (%)
No Data For consolidated ROE.
EBITDA Margin (%)
No Data For consolidated ROE.

bt_logoShare Holding Pattern

Summary (As on 31 Mar 2025)

bt_logoDeals

25 Jan, 2024BUY
MARSHALL WACE INVESTMENT STRATEGIES - SYSTEMATIC ALPHA PLUS FUND
Qty15950
Average Price₹1160.1
25 Jan, 2024BUY
MARSHALL WACE INVESTMENT STRATEGIESGTOPS FUND
Qty27571
Average Price₹1160.1
25 Jan, 2024BUY
MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUND
Qty106480
Average Price₹1160.1
25 Jan, 2024BUY
SOCIETE GENERALE
Qty1484323
Average Price₹1160.1
25 Jan, 2024SELL
BNP PARIBAS ARBITRAGE
Qty150001
Average Price₹1160.1
25 Jan, 2024SELL
BNP PARIBAS ARBITRAGE
Qty1484323
Average Price₹1160.1
*Single trade that involves transaction of a minimum quantity of 5 lakh shares or a minimum value of ₹ 10 crore.

bt_logoFAQ's

What was Aurobindo Pharma Ltd share price previously?
Aurobindo Pharma Ltd share price was down by -3.00% from the previous closing price of ₹1,257.80.
Who are peers of Aurobindo Pharma Ltd?
The peers of Aurobindo Pharma Ltd are Sun Pharmaceutical Industries Ltd, Divis Laboratories Ltd, Cipla Ltd, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Dr Reddys Laboratories Ltd, Lupin Ltd.
Who is/are the promoter/promoters of Aurobindo Pharma Ltd?
The promotor/promotors of Aurobindo Pharma Ltd are Kambam Nityananda Reddy, M Madan Mohan Reddy, P V Ramprasad Reddy, Savita Mahajan, Girish Paman Vanvari, P Sarath Chandra Reddy, Santanu Mukherjee, Deepali Pant Joshi, M R Kumar, Satakarni Makkapati.
What has been 52-week high of Aurobindo Pharma Ltd stocks?
The highest price of Aurobindo Pharma Ltd stock is ₹1,592.00 in the last 52-week.
What is the share price of Aurobindo Pharma Ltd (AUROPHARMA) today on NSE?
As on Apr 25, 2025 Aurobindo Pharma Ltd (AUROPHARMA)’s share price on NSE is Rs 1220.1
What is the market cap of Aurobindo Pharma Ltd (AUROPHARMA)?
The current market capitalisation of Aurobindo Pharma Ltd (AUROPHARMA) is 71,490.37 crores
What is Aurobindo Pharma Ltd Share symbol?
The symbol of Aurobindo Pharma Ltd is AUROPHARMA.
What is the PE ratio of Aurobindo Pharma Ltd (AUROPHARMA)?
The current PE ratio of Aurobindo Pharma Ltd (AUROPHARMA) is 20.44.
What is the PB ratio of Aurobindo Pharma Ltd (AUROPHARMA)?
The current PB ratio of Aurobindo Pharma Ltd (AUROPHARMA) is 2.31.
Today’s High & Low share prices of Aurobindo Pharma Ltd (AUROPHARMA) on NSE?
Today, the share price of Aurobindo Pharma Ltd (AUROPHARMA) on NSE touched a high of Rs 1268.9 and a low of Rs 1210
What price did Aurobindo Pharma Ltd (AUROPHARMA) shares open on the NSE today?
On NSE, the share price of Aurobindo Pharma Ltd (AUROPHARMA) opened at Rs 1257.9
What is the 52-week high of Aurobindo Pharma Ltd (AUROPHARMA)?
The 52-week high price of Aurobindo Pharma Ltd (AUROPHARMA) is Rs 1,592.00
What is the 52-week low of Aurobindo Pharma Ltd (AUROPHARMA)?
The 52-week low price of Aurobindo Pharma Ltd (AUROPHARMA) is Rs 1,010.00

bt_logoAbout Aurobindo Pharma

Aurobindo Pharma Ltd, incorporated in the year 1986, has its registered office in Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, 500038, 91-40-23736370, 91-40-23747340. The main industry in which Aurobindo Pharma Ltd operates is Pharmaceuticals - Indian - Bulk Drugs & Formln.

Auditor/Auditors for Aurobindo Pharma Ltd is/are Deloitte Haskins & Sells. In the main management, M R Kumar is chairman and is the company secretary for Aurobindo Pharma Ltd.

  • KNR
    Kambam Nityananda ReddyVice Chairman & M.D.
  • MMMR
    M Madan Mohan ReddyWhole-time Director
  • PVRR
    P V Ramprasad ReddyNon Executive Director
  • SM
    Savita MahajanIndependent Director
  • GPV
    Girish Paman VanvariIndependent Director
  • PSCR
    P Sarath Chandra ReddyNon Executive Director
  • SM
    Santanu MukherjeeIndependent Director
  • DPJ
    Deepali Pant JoshiIndependent Director
  • MRK
    M R KumarChairman & Independent Directo
  • SM
    Satakarni MakkapatiNon Executive Director

bt_logoTop Stories

DATA SOURCES: Corporate data, historical price & volume data published on this website have been sourced from CMOTS Internet Technologies Pvt. Ltd. BSE Quotes and NSE Quotes have been sourced from BSE Limited and NSE Data & Analytics Limited, respectively. All timestamps reflected here are in IST (Indian Standard Time). Stock Analysis section has been sourced from the mentioned partners.

DISCLAIMER: Any and all content on this website, including the tools/ analysis, is provided to you only for convenience and on an “as-is, as-available” basis without representation and warranties of any kind. The content and any output of such tools/ analysis is for informational purposes only and should not be relied upon or construed as investment advice or guarantee for any specific performance/ returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this website, you agree to the Terms of Service and Privacy Policy.